CV Sciences (CVSI) Net Income towards Common Stockholders (2011 - 2026)
CV Sciences (CVSI) posted Net Income towards Common Stockholders of -$643000.0 for Q1 2026, down 499.38% sequentially from $161000.0 in Q4 2025, and down 489.91% YoY from $164910.6 in Q1 2025.
CV Sciences (CVSI) Net Income towards Common Stockholders (2011 - 2026) Analysis & Trends
CV Sciences has reported Net Income towards Common Stockholders for 16 years, with the latest figure at -$643000.0 in Q1 2026.
- Quarterly Net Income towards Common Stockholders fell 489.91% year-over-year to -$643000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$1.1 million (up 30.3% YoY) and the FY2025 annual result came in at -$591000.0, up 75.31% from the prior year.
- Net Income towards Common Stockholders eased to -$643000.0 in Q1 2026 per CVSI's latest filing, from $161000.0 in the prior quarter.
- Over five years, Net Income towards Common Stockholders peaked at $5.7 million in Q1 2023 and troughed at -$3.6 million in Q2 2022.
- A 5-year average of -$546882.4 and a median of -$584000.0 in 2024 frame the typical range for Net Income towards Common Stockholders.
- The sharpest annual moves came in 2022 and 2023: Net Income towards Common Stockholders tumbled 2477.5% in 2022, then soared 369.79% in 2023.
- Over 5 years, Net Income towards Common Stockholders stood at -$2.3 million in 2022, then surged by 62.43% to -$869000.0 in 2023, then soared by 46.49% to -$465000.0 in 2024, then surged by 134.62% to $161000.0 in 2025, then plunged by 499.38% to -$643000.0 in 2026.
- According to Business Quant data, Net Income towards Common Stockholders over the past three periods registered -$643000.0, $161000.0, and -$382000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.96 Bn | 43.00 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.23 Bn | 39.58 Bn | 2.15 Bn | -576.00 Mn |
| 3 | Zoetis | 31.76 Bn | 30.08 Bn | 1.05 Bn | 866.00 Mn |
| 4 | Takeda Pharmaceutical | 28.68 Bn | 22.88 Bn | 5.10 Bn | 710.19 Mn |
| 5 | United Therapeutics | 22.27 Bn | 19.61 Bn | 683.80 Mn | 333.00 Mn |
| 6 | Viatris | 18.69 Bn | 17.81 Bn | 1.46 Bn | -118.80 Mn |
| 7 | Neurocrine Biosciences | 15.56 Bn | 15.17 Bn | 935.80 Mn | 144.40 Mn |
| 8 | Elanco Animal Health | 11.78 Bn | 11.25 Bn | 798.00 Mn | 54.00 Mn |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.97 Bn | - | - |
| 10 | CV Sciences | 4.10 Mn | 3.84 Mn | 1.45 Mn | -775,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -775,000.00 |
| Mar 31, 2026 | -643,000.00 |
| Dec 31, 2025 | 161,000.00 |
| Sep 30, 2025 | -382,000.00 |
| Jun 30, 2025 | -261,000.00 |
| Mar 31, 2025 | -109,000.00 |
| Dec 31, 2024 | -465,000.00 |
| Sep 30, 2024 | -456,000.00 |
| Jun 30, 2024 | -584,000.00 |
| Mar 31, 2024 | -628,000.00 |
| Dec 31, 2023 | -869,000.00 |
| Sep 30, 2023 | -447,000.00 |
| Jun 30, 2023 | -1.29 Mn |
| Mar 31, 2023 | 5.71 Mn |
| Dec 31, 2022 | -2.31 Mn |
| Sep 30, 2022 | -1.03 Mn |
| Jun 30, 2022 | -3.57 Mn |
| Mar 31, 2022 | -2.12 Mn |
| Dec 31, 2021 | -8.86 Mn |
| Sep 30, 2021 | -40,000.00 |